Follow the HLB이노베이션 stock price and the full directors' dealings record of the company, a publicly traded company based in South Korea. Shares are quoted on the KR market, under the authority of DART (FSS). Operating in the Health Care sector, HLB이노베이션 has published 83 public disclosures. Market capitalisation: €434.7bn. The latest transaction was filed on 7 July 2026 (Sale). Among the most active insiders: HLB. All data is free.
77
Insider Decl.
n/a
Thresholds
€8m
51 ops.
Buy Volume
n/a
7 ops.
Sell Volume
38Σ signal
Buys €8mn/a Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 27,205 of 28,932 companies
17.1
score / 100
Value
19
Quality
16
FCF yld-7.1%
Earn yld-7.7%
EV/EBITDA·
ROE-14%
Gross mgn13%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
HLB이노베이션 is a healthcare and pharmaceutical company listed on the XKRX market. It focuses on developing innovative solutions in the pharmaceutical field.